Artiva Biotherapeutics Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Artiva Biotherapeutics's earnings have been declining at an average annual rate of -7%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 92.1% per year.
Belangrijke informatie
-7.0%
Groei van de winst
-2.9%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 17.0% |
| Inkomstengroei | 92.1% |
| Rendement op eigen vermogen | -128.5% |
| Nettomarge | -111.2% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Geen updates
Opbrengsten en kosten
Hoe Artiva Biotherapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 29 | -33 | 13 | 48 |
| 31 Mar 24 | 33 | -26 | 14 | 47 |
| 31 Dec 23 | 33 | -29 | 14 | 50 |
| 31 Mar 23 | 5 | -63 | 21 | 49 |
| 31 Dec 22 | 5 | -59 | 21 | 44 |
| 31 Mar 22 | 3 | -41 | 14 | 30 |
| 31 Dec 21 | 2 | -72 | 13 | 42 |
| 30 Sep 21 | 1 | -66 | 10 | 38 |
| 31 Dec 20 | 0 | -18 | 4 | 14 |
Kwaliteitswinsten: ARTV is currently unprofitable.
Groeiende winstmarge: ARTV is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: ARTV is unprofitable, and losses have increased over the past 5 years at a rate of 7% per year.
Versnelling van de groei: Unable to compare ARTV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: ARTV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendement op eigen vermogen
Hoge ROE: ARTV has a negative Return on Equity (-128.48%), as it is currently unprofitable.